All posts tagged non-small cell lung cancer

  • Pills

    With early and obvious benefit of a targeted cancer drug, should expensive clinical testing continue?

    When a drug’s benefit is obvious in a clinical trial’s first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.

During his visit to University of Colorado Cancer Center, former NFL player Chris Draft met with lung cancer survivor Ellen Smith and her son.